CMPS Share Price Performance
Recent CMPS News & Updates
No updates
COMPASS Pathways plc Key Details
Last Reported Earnings
Mar 31, 2025
Next Reporting Earnings
Jul 31, 2025
- Earnings per share (EPS)
- -1.47
- Gross Margin
- 0%
- Net Profit Margin
- 0%
- Debt/Equity Ratio
- 15.6%
COMPASS Pathways plc Competitors
About CMPS
- Founded
- 2020
- Employees
- 166
- CEO
- WebsiteView website
COMPASS Pathways plc operates as a biotechnology company that focuses on mental health in the United Kingdom and the United States. It develops COMP360, a psilocybin therapy, which is in Phase III clinical trial for the treatment of treatment-resistant depression; and is in Phase II clinical trial for treating post-traumatic stress disorder and anorexia nervosa. The company was formerly known as COMPASS Rx Limited and changed its name to COMPASS Pathways plc in August 2020. The company was incorporated in 2020 and is headquartered in London, the United Kingdom.
U.K. Market Performance
- 7 Days: -1.1%
- 3 Months: 21.2%
- 1 Year: 10.1%
- Year to Date: 13.1%
Over the last 7 days, the market has dropped 1.1%, driven by a pullback of 3.4% in the Materials sector. On the other hand, the Healthcare has risen by 6.0%. In the last year, the market is actually up 10%. Looking forward, earnings are forecast to grow by 14% annually. Market details ›
Companies across the globe are beginning to pay attention to agentic AI. It’s also a term you’re likely to hear a lot during earnings season. In fact, it came up 26 times during...
Continue reading